Last reviewed · How we verify

BCG for Therapeutic Use

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Phase 3 active Small molecule

BCG for Therapeutic Use is a Live attenuated vaccine / Immunostimulant Small molecule drug developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. It is currently in Phase 3 development for Non-muscle invasive bladder cancer (intravesical immunotherapy), Therapeutic vaccine for infectious diseases (investigational). Also known as: BCG.

BCG (Bacillus Calmette-Guérin) activates the innate and adaptive immune system to enhance anti-tumor and anti-pathogen immune responses.

BCG (Bacillus Calmette-Guérin) activates the innate and adaptive immune system to enhance anti-tumor and anti-pathogen immune responses. Used for Non-muscle invasive bladder cancer (intravesical immunotherapy), Therapeutic vaccine for infectious diseases (investigational).

At a glance

Generic nameBCG for Therapeutic Use
Also known asBCG
SponsorAnhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Drug classLive attenuated vaccine / Immunostimulant
TargetPattern recognition receptors (TLRs); non-specific immune activation
ModalitySmall molecule
Therapeutic areaOncology / Immunology
PhasePhase 3

Mechanism of action

BCG is a live attenuated mycobacterium that stimulates both innate immunity through pattern recognition receptors and adaptive immunity through T-cell and B-cell activation. In therapeutic use, it acts as an immunostimulant to enhance the body's natural defense mechanisms against disease, particularly in cancer and infectious disease contexts. The mechanism involves toll-like receptor signaling and activation of dendritic cells, macrophages, and lymphocytes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about BCG for Therapeutic Use

What is BCG for Therapeutic Use?

BCG for Therapeutic Use is a Live attenuated vaccine / Immunostimulant drug developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., indicated for Non-muscle invasive bladder cancer (intravesical immunotherapy), Therapeutic vaccine for infectious diseases (investigational).

How does BCG for Therapeutic Use work?

BCG (Bacillus Calmette-Guérin) activates the innate and adaptive immune system to enhance anti-tumor and anti-pathogen immune responses.

What is BCG for Therapeutic Use used for?

BCG for Therapeutic Use is indicated for Non-muscle invasive bladder cancer (intravesical immunotherapy), Therapeutic vaccine for infectious diseases (investigational).

Who makes BCG for Therapeutic Use?

BCG for Therapeutic Use is developed by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (see full Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. pipeline at /company/anhui-zhifei-longcom-biologic-pharmacy-co-ltd).

Is BCG for Therapeutic Use also known as anything else?

BCG for Therapeutic Use is also known as BCG.

What drug class is BCG for Therapeutic Use in?

BCG for Therapeutic Use belongs to the Live attenuated vaccine / Immunostimulant class. See all Live attenuated vaccine / Immunostimulant drugs at /class/live-attenuated-vaccine-immunostimulant.

What development phase is BCG for Therapeutic Use in?

BCG for Therapeutic Use is in Phase 3.

What are the side effects of BCG for Therapeutic Use?

Common side effects of BCG for Therapeutic Use include Local irritation at administration site, Fever, Fatigue, BCG-itis (systemic BCG infection).

What does BCG for Therapeutic Use target?

BCG for Therapeutic Use targets Pattern recognition receptors (TLRs); non-specific immune activation and is a Live attenuated vaccine / Immunostimulant.

Related